Johnson & Johnson applies for vaccine approval in the EU – South Africa mutation


 The  US corporation Johnson & Johnson applied for approval of its Covid-19 vaccine in the EU on Tuesday.

This is also good news for Austria. True, there are only 2.5 million of the 30.5 million doses of vaccine ordered by Johnson & Johnson. But the vaccination should be against the South African variant B.1.351 Act. South Africa, which temporarily stopped the AstraZeneca vaccinations, is already being administered by Johnson & Johnson as part of an implementation study. Let it be proven Mkhize said that the Johnson & Johnson vaccination was effective against the variant prevalent in South Africa. “© The  necessary approval procedures for use in South Africa are currently ongoing.”

© The  vaccine called “Janssen” should now be tested by the EU medicines agency EMA. It is also currently being tested in the United States.

According to a worldwide study, the Johnson & Johnson vaccine has an effectiveness of 66 percent. In a study in the USA, however, the effectiveness was higher at 72 percent. © The  study comprised a total of around 44,000 participants on three continents. According to the company, no serious, undesirable side effects were found.

In South Africa, the vaccine showed an effectiveness of 57 percent in the mutant. © The  US health authority FDA set a minimum value of 50 percent for possible approval last year.

Only one dose needed

Compared to the vaccines from Biontech / Pfizer and Moderna, the preparation from Johnson & Johnson offers the advantage that a single dose should be sufficient. In addition, the preparation does not have to be stored frozen, which makes distribution easier. © The  different study results are apparently also related to the more contagious virus variants.

© The  competitors Biontech / Pfizer and Moderna have set a high standard with their already approved vaccines – which are based on so-called messenger RNA (mRNA) and thus a completely new technology. In the decisive studies, they showed an effectiveness of 95 and 94 percent respectively. In its study, J&J had set itself the prevention of moderate to severe Covid-19 courses as the main goal – the vaccine was therefore 85 percent effective across all regions in order to stop the course of the disease and avoid hospitalization. This “will potentially protect hundreds of millions of people from serious and fatal consequences,” said J&J research director Paul Stoffels.(what, dpa)

[ source link ]

Johnson Johnson applies vaccine approval South Africa mutation


Please enter your comment!
Please enter your name here